# Newron Pharmaceuticals SPA clinical trials: 22 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Newron Pharmaceuticals SPA as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Newron Pharmaceuticals SPA: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/newron-pharmaceuticals-spa

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 22, 2025 | NCT07184619 | Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | Newron Pharmaceuticals SPA | Phase 3 | Recruiting | Treatment-resistant Schizophrenia | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07184619) |
| July 8, 2020 | NCT04461119 | Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia | Newron Pharmaceuticals SPA | Phase 2 | Completed | Schizophrenia | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04461119) |
| February 26, 2018 | NCT03446274 | An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects | Newron Pharmaceuticals SPA | Phase 1 | Unknown | Healthy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03446274) |
| June 3, 2016 | NCT02790034 | Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms | Newron Pharmaceuticals SPA | Phase 2/3 | Terminated | Rett Syndrome | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02790034) |
| December 8, 2015 | NCT02624167 | A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia | Newron Pharmaceuticals SPA | Phase 2 | Completed | Chronic Schizophrenia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02624167) |
| October 7, 2013 | NCT01955564 | A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers. | Newron Pharmaceuticals SPA | Phase 1 | Completed | Schizophrenia | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01955564) |
| June 15, 2011 | NCT01374113 | Safinamide Renal Impairment Trial | Newron Pharmaceuticals SPA | Phase 1 | Completed | Renal Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01374113) |
| January 31, 2011 | NCT01286935 | 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD | Newron Pharmaceuticals SPA | Phase 3 | Completed | Parkinson's Disease | 544 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01286935) |
| December 22, 2010 | NCT01264861 | A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging | Newron Pharmaceuticals SPA | Phase 2 | Terminated | Parkinson Disease | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01264861) |
| September 29, 2010 | NCT01211587 | A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease | Newron Pharmaceuticals SPA | Phase 2 | Completed | Parkinson's Disease With Cognitive Impairments | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01211587) |
| August 24, 2010 | NCT01187966 | Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease | Newron Pharmaceuticals SPA | Phase 3 | Completed | Parkinson's Disease | 669 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01187966) |
| April 29, 2010 | NCT01113320 | Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects | Newron Pharmaceuticals SPA | Phase 2 | Completed | Parkinson's Disease | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01113320) |
| December 9, 2009 | NCT01028586 | MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) | Newron Pharmaceuticals SPA | Phase 3 | Terminated | Idiopathic Parkinson's Disease | 507 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01028586) |
| December 7, 2009 | NCT01027169 | A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics | Newron Pharmaceuticals SPA | Phase 1 | Completed | Hepatic Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01027169) |
| December 4, 2009 | NCT01026428 | A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics | Newron Pharmaceuticals SPA | Phase 1/2 | Completed | Idiopathic Parkinson's Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01026428) |
| November 25, 2009 | NCT01019824 | Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain | Newron Pharmaceuticals SPA | Phase 3 | Completed | Pain | 411 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01019824) |
| March 19, 2009 | NCT00865579 | Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients | Newron Pharmaceuticals SPA | Phase 3 | Terminated | Parkinson's Disease | 964 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00865579) |
| August 15, 2008 | NCT00736151 | Phase II Dose Titration Study in Patients With Neuropathic Pain | Newron Pharmaceuticals SPA | Phase 2 | Completed | Neuropathic Pain | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00736151) |
| March 25, 2008 | NCT00643045 | Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist | Newron Pharmaceuticals SPA | Phase 3 | Completed | Idiopathic Parkinson's Disease | 269 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00643045) |
| March 25, 2008 | NCT00642889 | Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist... | Newron Pharmaceuticals SPA | Phase 3 | Completed | Parkinson's Disease | 227 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00642889) |
| March 3, 2008 | NCT00627640 | Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa | Newron Pharmaceuticals SPA | Phase 3 | Completed | Idiopathic Parkinson's Disease | 549 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00627640) |
| January 31, 2008 | NCT00605683 | MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist | Newron Pharmaceuticals SPA | Phase 3 | Completed | Idiopathic Parkinson's Disease | 679 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00605683) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 2/3 | 1 |
| Phase 3 | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Terminated | 4 |
| Unknown | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Parkinson Disease | 12 |
| Schizophrenia | 3 |
| Neuralgia | 1 |
| Liver Diseases | 1 |
| Rett Syndrome | 1 |
| Dyskinesias | 1 |
| Pain | 1 |
| Neuroma | 1 |
| Renal Insufficiency | 1 |
| Lymphoma, Follicular | 1 |
| Schizophrenia, Treatment-Resistant | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Orthopedics practices in the United States](https://specstream.ai/data/businesses/orthopedics-practices/united-states)
- [Bottled water companies in the United States](https://specstream.ai/data/businesses/bottled-water-companies/united-states)
- [Motels in the United States](https://specstream.ai/data/businesses/motels/united-states)
- [Bangladeshi restaurants in the United States](https://specstream.ai/data/businesses/bangladeshi-restaurants/united-states)
- [Media agencies in the United States](https://specstream.ai/data/businesses/media-agencies/united-states)
